Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Naproxcinod, a nitric oxide-releasing NSAID derivative, significantly improved skeletal muscle strength and fatigue resistance in sedentary and exercise mice, reducing inflammatory infiltration and fibrotic deposition in the myocardium and diaphragm. In addition to its anti-inflammatory activity, Naproxcinod is a promising candidate for the treatment of Duchenne muscular dystrophy.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | Naproxcinod, a nitric oxide-releasing NSAID derivative, significantly improved skeletal muscle strength and fatigue resistance in sedentary and exercise mice, reducing inflammatory infiltration and fibrotic deposition in the myocardium and diaphragm. In addition to its anti-inflammatory activity, Naproxcinod is a promising candidate for the treatment of Duchenne muscular dystrophy. |
別名 | AZD3582, Nitronaproxen, AZD-3582, Naproxen-N-butyl nitrate, HCT3012, AZD 3582 |
分子量 | 347.36 |
分子式 | C18H21NO6 |
CAS No. | 163133-43-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Naproxcinod 163133-43-5 Naproxen-N-butyl Nitrate AZD3582 Nitronaproxen AZD-3582 HCT-3012 Naproxen-N-butyl nitrate HCT3012 HCT 3012 AZD 3582 Inhibitor inhibitor inhibit